JP2011157403A5 - - Google Patents

Download PDF

Info

Publication number
JP2011157403A5
JP2011157403A5 JP2011116366A JP2011116366A JP2011157403A5 JP 2011157403 A5 JP2011157403 A5 JP 2011157403A5 JP 2011116366 A JP2011116366 A JP 2011116366A JP 2011116366 A JP2011116366 A JP 2011116366A JP 2011157403 A5 JP2011157403 A5 JP 2011157403A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
day
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011116366A
Other languages
English (en)
Japanese (ja)
Other versions
JP5623335B2 (ja
JP2011157403A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011157403A publication Critical patent/JP2011157403A/ja
Publication of JP2011157403A5 publication Critical patent/JP2011157403A5/ja
Application granted granted Critical
Publication of JP5623335B2 publication Critical patent/JP5623335B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011116366A 1999-06-01 2011-05-24 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 Expired - Lifetime JP5623335B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13703899P 1999-06-01 1999-06-01
US60/137,038 1999-06-01
US18533600P 2000-02-29 2000-02-29
US60/185,336 2000-02-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000620987A Division JP4817503B2 (ja) 1999-06-01 2000-06-01 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012130177A Division JP2012176983A (ja) 1999-06-01 2012-06-07 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2014165702A Division JP5960762B2 (ja) 1999-06-01 2014-08-18 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Publications (3)

Publication Number Publication Date
JP2011157403A JP2011157403A (ja) 2011-08-18
JP2011157403A5 true JP2011157403A5 (enExample) 2012-07-26
JP5623335B2 JP5623335B2 (ja) 2014-11-12

Family

ID=26834850

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2000620987A Expired - Lifetime JP4817503B2 (ja) 1999-06-01 2000-06-01 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2007136041A Pending JP2007277253A (ja) 1999-06-01 2007-05-22 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2011116366A Expired - Lifetime JP5623335B2 (ja) 1999-06-01 2011-05-24 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2012130177A Pending JP2012176983A (ja) 1999-06-01 2012-06-07 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2014165702A Expired - Lifetime JP5960762B2 (ja) 1999-06-01 2014-08-18 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2016060029A Withdrawn JP2016121184A (ja) 1999-06-01 2016-03-24 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000620987A Expired - Lifetime JP4817503B2 (ja) 1999-06-01 2000-06-01 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2007136041A Pending JP2007277253A (ja) 1999-06-01 2007-05-22 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012130177A Pending JP2012176983A (ja) 1999-06-01 2012-06-07 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2014165702A Expired - Lifetime JP5960762B2 (ja) 1999-06-01 2014-08-18 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2016060029A Withdrawn JP2016121184A (ja) 1999-06-01 2016-03-24 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Country Status (28)

Country Link
US (5) US6955810B2 (enExample)
EP (3) EP2314315B1 (enExample)
JP (6) JP4817503B2 (enExample)
CN (1) CN1309419C (enExample)
AU (2) AU783989B2 (enExample)
BG (1) BG65579B1 (enExample)
BR (1) BR0011250A (enExample)
CA (1) CA2375827C (enExample)
CY (1) CY1116042T1 (enExample)
CZ (1) CZ300710B6 (enExample)
DK (2) DK2314315T3 (enExample)
EA (1) EA011384B1 (enExample)
EE (1) EE200100651A (enExample)
ES (2) ES2529706T3 (enExample)
GE (1) GEP20063774B (enExample)
HK (1) HK1043320A1 (enExample)
HU (1) HUP0202568A3 (enExample)
IL (2) IL146508A0 (enExample)
IS (1) IS6179A (enExample)
MX (1) MXPA01012388A (enExample)
NO (1) NO20015864L (enExample)
NZ (1) NZ515686A (enExample)
PT (2) PT1488806E (enExample)
SI (2) SI2314315T1 (enExample)
SK (1) SK17232001A3 (enExample)
TR (1) TR200103432T2 (enExample)
WO (1) WO2000072881A1 (enExample)
YU (1) YU85501A (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2314315T3 (en) 1999-06-01 2015-02-02 Biogen Idec Inc Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases
MXPA03009390A (es) 2001-04-13 2004-01-29 Biogen Inc Anticuerpos para integrina vla-1.
AU2003215298A1 (en) * 2002-02-14 2003-09-04 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
MXPA05004563A (es) * 2002-11-01 2005-07-26 Boys Town Nat Res Hospital Ligando inducible para la integrina alfa1beta1 y usos.
WO2005004800A2 (en) * 2003-06-20 2005-01-20 Morehouse School Of Medicine Trypanosome derived apoptotic factors (taf)
US20080093950A1 (en) * 2003-12-09 2008-04-24 Electrotechnologies Selem. Inc Polyphase Claw-Pole Machines With a Segmented Magnetic Circuit
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) * 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
EP2839843B1 (en) * 2006-05-25 2018-06-20 Biogen MA Inc. VLA-1 antagonist for use in treating stroke
EP2279209A2 (en) * 2008-05-09 2011-02-02 Ablynx NV Amino acid sequences directed against integrins and uses thereof
PT2582391T (pt) * 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
AU2012212194B2 (en) * 2011-02-03 2017-05-04 Santarus, Inc. Selection and treatment of subjects
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
US11312775B2 (en) 2017-07-20 2022-04-26 University Of Virginia Patent Foundation Methods for treatment or prevention of a neurological immunity disorder

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991010737A1 (en) * 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
US5871907A (en) * 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993013798A1 (en) 1992-01-13 1993-07-22 Biogen, Inc. Treatment for asthma
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
ES2114183T5 (es) 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
US6111598A (en) * 1993-11-12 2000-08-29 Peveo, Inc. System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
AU703152B2 (en) 1994-01-25 1999-03-18 Biogen Ma Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
DK0759302T3 (da) * 1994-04-26 2000-11-13 Kanebo Ltd Middel mod rheumatoid arthritis
JPH08131185A (ja) * 1994-11-14 1996-05-28 Sumitomo Electric Ind Ltd マウスｖｌａ−１分子に対するモノクローナル抗体
JPH08160972A (ja) 1994-12-01 1996-06-21 Sega Enterp Ltd エフェクト制御方法、制御装置およびこれを利用したカラオケ装置
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9516399D0 (en) 1995-08-10 1995-10-11 Camelot Superabsorbents Ltd Process for the production of water-absorbing compositions
WO1997008320A1 (en) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimera animal and its method of manufacture
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
FR2745912B1 (fr) * 1996-03-08 1998-05-29 Lorraine Laminage Procede et dispositif de controle de la soudabilite de toles sandwich
US6127524A (en) * 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
EP1079843B1 (en) 1998-05-22 2007-04-18 Boys Town National Research Hospital Use of alfa1beta1 integrin receptor inhibitors and tgf- beta1 inhibitors in the treatment of kidney disease
DE19831710A1 (de) * 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
HK1039341A1 (zh) 1998-10-06 2002-04-19 Biogen Idec Ma Inc. α1β1合成(「α1β1」)I-领域的结晶体及其使用
PT1173201E (pt) * 1999-04-22 2005-08-31 Biogen Idec Inc Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
DK2314315T3 (en) 1999-06-01 2015-02-02 Biogen Idec Inc Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases
WO2000078221A1 (de) 1999-06-17 2000-12-28 Kai Desinger Chirurgische sonde zur minimal invasiven gewebeentnahme
WO2001073444A2 (en) 2000-03-28 2001-10-04 Cambridge University Technical Services Limited Receptor/peptide crystal structure for identification of inhibitors
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US7153944B2 (en) 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
MXPA03009390A (es) 2001-04-13 2004-01-29 Biogen Inc Anticuerpos para integrina vla-1.
AU2003215298A1 (en) 2002-02-14 2003-09-04 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
WO2004013180A2 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
WO2005019200A2 (en) 2003-08-14 2005-03-03 Icos Corporation Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
WO2005016883A2 (en) 2003-08-14 2005-02-24 Icos Corporation Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP2839843B1 (en) 2006-05-25 2018-06-20 Biogen MA Inc. VLA-1 antagonist for use in treating stroke
JP4951596B2 (ja) 2008-07-31 2012-06-13 株式会社日立製作所 冷却システム及び電子装置
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
AU2012212194B2 (en) 2011-02-03 2017-05-04 Santarus, Inc. Selection and treatment of subjects
WO2013105161A1 (ja) 2012-01-11 2013-07-18 パナソニック株式会社 圧接型半導体装置及びその製造方法
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物

Similar Documents

Publication Publication Date Title
JP2011157403A5 (enExample)
JP2022031635A5 (enExample)
JP2013198490A5 (enExample)
JP2014526898A5 (enExample)
JP2012121878A5 (enExample)
JP2010526028A5 (enExample)
HRP20250807T1 (hr) Protutijela koja vežu ljudski cgrp receptor
JP2014110800A5 (enExample)
JP2010536384A5 (enExample)
JP2012070737A5 (enExample)
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
JP2009225799A5 (enExample)
RU2018112861A (ru) Стабильные антитела, связывающиеся с несколькими антигенами
JP2014205674A5 (enExample)
RU2017128882A (ru) Антитела к биотину и способы их применения
HRP20190008T4 (hr) Prevencija i liječenje sinukleinopatske i amiloidogene bolesti
RU2016100892A (ru) Антитела против tweakr и их применение
JP2013538057A5 (enExample)
JP2014511179A5 (enExample)
JP2010500371A5 (enExample)
MX353931B (es) Anticuerpos que se unen a ox40 y sus usos.
JP2014502955A5 (enExample)
JP2017052784A5 (enExample)
JP2014519334A5 (enExample)
JP2016530223A5 (enExample)